A number of other equities research analysts also recently commented on the company. Cowen set a $110.00 price objective on Guardant Health and gave the company a buy rating in a research report on Wednesday, August 7th. Canaccord Genuity restated a buy rating and issued a $125.00 target price on shares of Guardant Health in a report on Friday, November 8th. William Blair restated an outperform rating on shares of Guardant Health in a report on Friday, November 8th. Zacks Investment Research raised Guardant Health from a hold rating to a strong-buy rating and set a $84.00 target price for the company in a report on Tuesday, November 12th. Finally, JPMorgan Chase & Co. upped their target price on Guardant Health from $90.00 to $135.00 and gave the company an overweight rating in a report on Wednesday, August 7th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $107.60.
Shares of Guardant Health stock traded up $0.40 during trading on Tuesday, hitting $73.98. The stock had a trading volume of 508,099 shares, compared to its average volume of 1,073,320. The business has a fifty day moving average of $73.09 and a two-hundred day moving average of $81.33. Guardant Health has a fifty-two week low of $32.33 and a fifty-two week high of $112.21. The firm has a market cap of $6.95 billion, a P/E ratio of -26.42 and a beta of 0.22.
In other news, VP Timothy P. Eckersley sold 2,364 shares of Guardant Health stock in a transaction on Monday, October 28th. The stock was sold at an average price of $118.24, for a total transaction of $279,519.36. Also, Director Ian T. Clark sold 538 shares of Guardant Health stock in a transaction on Monday, November 25th. The shares were sold at an average price of $78.17, for a total value of $42,055.46. Following the transaction, the director now owns 1,840 shares in the company, valued at approximately $143,832.80. The disclosure for this sale can be found here. Over the last three months, insiders sold 5,027,544 shares of company stock worth $387,115,267. 13.00% of the stock is currently owned by insiders.
Hedge funds have recently bought and sold shares of the stock. Advantage Investment Management LLC boosted its position in Guardant Health by 200.0% during the second quarter. Advantage Investment Management LLC now owns 450 shares of the company’s stock valued at $39,000 after purchasing an additional 300 shares during the last quarter. HM Payson & Co. acquired a new position in Guardant Health in the 2nd quarter worth about $43,000. Oppenheimer Asset Management Inc. purchased a new stake in shares of Guardant Health during the 2nd quarter worth about $62,000. Whittier Trust Co. purchased a new stake in shares of Guardant Health during the 3rd quarter worth about $62,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Guardant Health during the 2nd quarter valued at about $76,000. Institutional investors and hedge funds own 78.19% of the company’s stock.
About Guardant Health
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.
Further Reading: How is diluted EPS different from basic EPS?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.